Recent Updates
Recently added Catalysts
GRAL Positive Sentiment

GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

Key Takeaway: GRAIL, Inc. announced that its management will present at the 2026 Jefferies Global Healthcare Conference on June 3 at 7:35 a.m. ET. The company is dedicated to early cancer detection, utilizing advanced technologies to improve patient outcomes. The event will be accessible via live and archived webcasts on GRAIL's investor relations website.
Price reaction · baseline $67.86 (2026-05-21 close) · hit pre-market · 2 other GRAL headline(s) in the window, move may be shared
day 0 close · peak
-1%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • GRAIL is focused on early cancer detection, which is crucial for treatment success.
  • The company's innovative use of next-generation sequencing and machine learning is promising.
  • The presentation at a major healthcare conference highlights GRAIL's visibility in the industry.

Full Press Release Details

MENLO PARK, Calif.,May 21, 2026/PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3 at 7:35 a.m. ET.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website atinvestors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

Frequently Asked Questions

When will GRAIL present at the Jefferies conference?

GRAIL will present on June 3, 2026, at 7:35 a.m. ET.

How can I access the GRAIL presentation?

The presentation will be available via live and replay webcasts on GRAIL's investor relations website.

What is GRAIL's mission?

GRAIL aims to detect cancer early when it can be cured using advanced technologies.

Where is GRAIL headquartered?

GRAIL is headquartered in Menlo Park, California.

Last updated: May 22, 2026